HMOX1 and plasma cell myeloma: LMK235 at concentrations of 1–5 μM showed potent antimyeloma activity and downregulated heme oxygenase-1, which is an NFE2L2 transcription factor-regulated gene that may be a potential target for chemoresistant multiple myeloma treatment [49].